Sagar Lonial, MD, FACP, details additional agents of interest outside CAR T-cell therapies in multiple myeloma including the recently approved agents elranatamab and talquetamab.
Robert Mancini, PharmD, discusses current DLBCL (diffuse large B cell lymphoma) management approaches, relapse rates, frontline, and subsequent therapies, including emerging treatments like bispecific T-cell engagers and monoclonal antibodies.
/PRNewswire/ The National Comprehensive Cancer Network® (NCCN®) 2023 Annual Congress: Hematologic Malignancies™ returns to San Francisco this week, for the.